gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Article

Send article

YAP and TAZ expression in benign pediatric brain tumours with high levels in choroid plexus papillomas

Expression von YAP und TAZ in gutartigen pädiatrischen Hirntumoren, insbesondere Plexuspapillomen

Meeting Abstract

Search Medline for

  • Laura Hero - Universitätsklinikum Köln, Klinik für Neurochirurgie, Köln, Deutschland
  • Roland Goldbrunner - Universitätsklinikum Köln, Klinik für Neurochirurgie, Köln, Deutschland
  • presenting/speaker Marco Timmer - Universitätsklinikum Köln, Klinik für Neurochirurgie, Köln, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocP184

doi: 10.3205/22dgnc499, urn:nbn:de:0183-22dgnc4995

Published: May 25, 2022

© 2022 Hero et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: YAP and TAZ as down-stream effectors of the hippo pathway play a role in tumorigenesis, tumor progression and metastasis in different tumor entities, among these malign and benign brain tumors. Our goal was to examine YAP and TAZ expression in different pediatric low grade brain tumors.

Methods: Tumor and control tissues were collected during neurosurgical resection and classified with WHO 2007 classification. YAP and TAZ expression were investigated via PCR and Western Blotting in benign pediatric brain tumors. Diagnoses included dysembryoplastic neuroepithelial tumor (DNET, n=3), choroid plexus papilloma (n=6), ganglioglioma (n=6), neurofibroma (n=4) and craniopharyngioma (n=5).

Results: TAZ protein expression was significantly higher in choroid plexus papilloma compared to control tissue (z=2.582, adjusted p=0.0491, Kruskal Wallis test) and DNET (z=3.012, adjusted p=0.0259, Kruskal Wallis test). Western Blot bar marks of YAP and TAZ were also intensified in contrast to high-grade medulloblastoma and glioblastoma (no quantitative data). mRNA expression of YAP showed significant difference in choroid plexus papilloma compared to control tissue (z=2.969, adjusted p=0.0149, Kruskal Wallis test), DNET (z=3.100, adjusted p=0.0194, Kruskal Wallis test) and ganglioglioma (z=3.674, adjusted p=0.0024, Kruskal Wallis test). TAZ mRNA was also high expressed in ganglioglioma and neurofibroma compared to control group (z=3.3138, adjusted p=0.0085 and z=3.744, adjusted p=0.0009, Kruskal Wallis test). Neurofibroma group also showed significantly higher gene expression compared to every other group (DNET: q=5.107, adjusted p=0.0150; CPP: q=6.305, adjusted p=0.0025; GG: q=4.285, adjusted p=0.0494; CP: q=5.424, adjusted p=0.0093; One-way ANOVA).

Conclusion: Higher expression rates of YAP and TAZ could indicate a possible role of the Hippo pathway effectors in tumorigenesis of choroid plexus papilloma, ganglioglioma and neurofibroma.